Hakon Leffler
11 – 20 of 167
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
Galectin-3 Decreases 4-1BBL Bioactivity by Crosslinking Soluble and Membrane Expressed 4-1BB
(
- Contribution to journal › Article
-
Mark
Design and synthesis of novel 3-triazolyl-1-thiogalactosides as galectin-1, -3 and -8 inhibitors
(
- Contribution to journal › Article
-
Mark
Discovery and Optimization of the First Highly Effective and Orally Available Galectin-3 Inhibitors for Treatment of Fibrotic Disease
(
- Contribution to journal › Article
-
Mark
Galectin-3 inhibitor GB0139 protects against acute lung injury by inhibiting neutrophil recruitment and activation
(
- Contribution to journal › Article
-
Mark
Engineering the Ligand Specificity of the Human Galectin-1 by Incorporation of Tryptophan Analogues
(
- Contribution to journal › Article
-
Mark
Novel Selective Galectin-3 Antagonists Are Cytotoxic to Acute Lymphoblastic Leukemia
(
- Contribution to journal › Article
-
Mark
Galectin-9 Signaling Drives Breast Cancer Invasion through Extracellular Matrix
(
- Contribution to journal › Article
-
Mark
Site-specific N-glycan profiles of α5β1 integrin from rat liver
(
- Contribution to journal › Article
-
Mark
Installation of O-glycan sulfation capacities in human HEK293 cells for display of sulfated mucins
(
- Contribution to journal › Article
- 2021
-
Mark
Synthesis and Biological Studies of O3-Aryl Galactosides as Galectin Inhibitors
(
- Contribution to journal › Article